(NBY) Is Cranking First Thing On Major Breaking News (Up Approx. 12% Early!)

Time's of the utmost importance, so pay close attention. (NBY) Is Cranking First Thing On Major Breaking News (Up Approx. 12% Early!) January 9th Dear Reader, Time's of the utmost importance, so pay close attention. NBY is off to a hot start this morning and it may just only be the beginning. Up approximately 12%, NBY could become a volatile situation based on its [low float]( of roughly 6.24Mn shares and huge news: [NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network]( Another key thing to focus on is NBY's technicals. As I mentioned in the report below, NBY had several oversold [technical indicators]( that suggested a healthy reversal could be on the horizon. After bottoming out below $.15 yesterday, could NBY be poised for a return to previous highs as it may be undervalued at the time being? With a 9-Day and 14-Day Relative Strength Index both below 25% going into today's session, NBY needs immediate focus. Drop everything and get NBY on your screen before it's too late. -----  Did you take off before this past Friday's closing bell? Listen. It's the first week of the year. We understand if you felt a little gassed and wanted to peel out early. That said, if you stuck around, our midweek alert surged BIG TIME. Even with the overall Nasdaq Composite having a rough week, we were able to identify a hidden gem capable of making a short term surge. Moving from a Wednesday open of $2.87 to a Friday high of $3.43, our latest alert ran approximately 19%. Pair that runner with my last two profiles which popped approx. 95% and 39%, and you're looking at 3 straight champs (over approx. 150% combined)! Wow. That was a mouthful. But here's another... Right now, I've got a NYSE American past champ coming back your way. And the last time I brought it to you, it was backed by catalyst news that allowed this profile to rocket over approx. 100% from one session to the next. The cool thing? That's not the only major breakout this profile has put together after my alert. Previous to its last breakout, this profile had made another major run of over 90% (approximate). I know that's a lot to take in right now, so let's focus on what's most pressing this second... First off, this is a [low float profile]( with fewer 7Mn shares in its float which means volatility will need to be on watch. [Oversold technicals.]( technical indicators are leaning towards oversold territory suggesting a mega bounce/healthy reversal could soon be in the cards. How about an [analyst target]( suggesting over 1,800% potential upside from its closing valuation Friday? Drop everything right now and pull up: *NovaBay Pharmaceuticals, Inc. (NBY)* NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products. And right now, NBY has several potential breakout catalysts to sink your teeth into. Check them out: No. 1: Explosive Volatility Potential Based On NBY's Float Is Must-Know Material. No. 2: An Analyst Targets Could Suggest As Much As 1,800% Potential Upside. No. 3: Oversold Technicals Indicators Point Towards A Potential Bounce/Reversal Scenario Brewing. No. 4: NBY's Avenova Allograft Officially Launches (To Take On $400+Mn Market). But more on those in a second... Corporate Overview - The Inner-Workings Of NBY Established Brands in Three Verticals - Avenova - #1 doctor-recommended antimicrobial lid & lash spray in the U.S. dry eye market - DERMAdoctor - more than 30 highly effective, problem-solving dermatological products - PhaseOne and NeutroPhase cutting-edge wound care technology Avenova - Science for sore eyes. - No. 1 Doctor-Recommended Antimicrobial Lid & Lash Spray - Kills a broad spectrum of bacteria and helps relieve chronic eye conditions like dry eye, blepharitis, styes, contact lens discomfort and inflammation - 510(k) FDA-cleared formulation is the only known stable, truly pure HOCI commercial solution - Manufactured and lab tested in the U.S. and clinically proven to be the most effective lid & lash solution available without a prescription - 80-100 times more potent than Clorox bleach yet completely nontoxic Avenova Opp's for Growth DERMAdoctor: A Well-Established Name in the Expanding Skincare Industry Significant Global Growth Opp. - Cosmetic skincare products estimated to reach $185Bn by 2027 - The skincare segment is growing faster than any other part of the beauty industry Grab Source And Key Details Here: [Company Presentation.]( ----- And as mentioned above, NBY has several potential catalysts that could help provide a breakout spark. Check these out: No. 1: Explosive Volatility Potential Based On NBY's Float Is Must-Know Material. According to the [Yahoo Finance]( website, NBY has a low float. The website reports this profile to have approximately 6.24Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could positive company early in 2024 provide a breakout spark for NBY? No. 2: An Analyst Targets Could Suggest As Much As 1,800% Potential Upside. Edward Woo, an analyst at [Ascendiant Capital Markets,]( has tagged NBY with a $3.50 price target. From Monday's opening valuation, that provides NBY with an incredible upside potential of 1,800+%. Here's some key highlights from his report: - Avenova products sales: Avenova product sales were $2.4Mn. The company also had $0.1Mn of NeutroPhase and PhaseOne wound careproduct sales. - DERMAdoctor contribution: DERMAdoctor sales were $0.8Mn. - DERMAdoctor: In September 2021, NovaBay announced the acquisition ofprivately held DERMAdoctor for ~$12Mn (in cash). DERMAdoctor produce sand sells more than 30 products under lines that include Ain’t Misbehavin’, Calm Cool + Corrected, Kakadu C, KP Duty, and Wrinkle Revenge. Its product sare designed to address acne, aging skin, dark spots, dry skin, eczema, and many other skin conditions. DERMAdoctor sells its products through major retailers such as Macy’s, QVC, Costco, digital beauty retailers such as SkinStoreand Amazon, as well as its own website. DERMAdoctor also has a large and growing network of international distributors and retailers. DERMAdoctor’s management has joined the NovaBay management team. - DERMAdoctor new focus: The company is now shifting its strategy in its skincare segment away from new product development to focus more on driving sales of top-selling products through its most efficient sales channels. As part of this, Dr. Jeff Kunin and Dr. Audrey Kunin (founders of DERMAdoctor) will retire in November 2023. - Management long term positive: NovaBay is making good progress to market its Avenova product to the 41 million Americans ($600Mn market opp.) who suffer from blepharitis and related eye symptoms. In addition, the acquisition of DERMAdoctor allows strong growth and synergy opp's in the global market for cosmetic skincare products. NovaBay plans to launch a broad range of complementary eye and skin care products. The company also plans to leverage operational synergies and sales/distribution relationships. ----- No. 3: Oversold Technicals Indicators Point Towards A Potential Bounce/Reversal Scenario Brewing. Rewind to 12:00PM EST Monday. [Barchart]( was reporting multiple oversold technical indicators for NBY. These technicals could be signaling a healthy reversal could be approaching in the near term. Here's the definition of a "reversal" from Investopedia: "A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart." Here's the technicals to pay close attention to: - 9-Day Relative Strength Index: 24.63% - 14-Day Relative Strength Index: 26.06% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. - 14-Day Raw Stochastic: 14.02% - 14-Day Williams %R: 85.98% As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued. Keep an eye on these technicals closely. ----- No. 4: NBY's Avenova Allograft Officially Launches (To Take On $400+Mn Market). NovaBay Pharmaceuticals, Inc. has [officially launched Avenova Allograft]( a prescription product designed for eyecare professionals in the U.S. through its physician-dispensed channel. Manufactured using BioStem Technologies, Inc.'s proprietary process, Avenova Allograft serves as a protective covering during the repair of ocular surfaces. The commercial release follows a prior agreement granting NovaBay the right to market BioStem Technologies' Amniotic Tissue Allograft under the Avenova brand. Positioned to compete in the [global ophthalmology amniotic membrane market]( valued at $403.6Mn in 2022 and expected to grow at a rate of 9.8% annually from 2023 to 2030, Avenova Allograft represents NovaBay's strategic entry into this expanding market. Justin Hall, CEO and General Counsel of NovaBay shared: "Avenova Allograft is a valuable addition to our high-quality, differentiated eyecare franchise and allows us to provide another solution for the professionals who specialize in treating eye conditions. We have fostered strong relationships with eyecare professionals nationwide including thousands of optometrists and ophthalmologists who recommend, prescribe, and sell Avenova-branded products every day. Sales in our physician-dispensed channel continue to grow, providing us with a terrific platform to launch this innovative product." ----- 4 Pressing Potential Breakout Catalysts - NBY's Recap No. 1: Explosive Volatility Potential Based On NBY's Float Is Must-Know Material. No. 2: An Analyst Targets Could Suggest As Much As 1,800% Potential Upside. No. 3: Oversold Technicals Indicators Point Towards A Potential Bounce/Reversal Scenario Brewing. No. 4: NBY's Avenova Allograft Officially Launches (To Take On $400+Mn Market). ----- Coverage is officially initiated on NovaBay Pharmaceuticals, Inc. (NBY). When updates pop up moving forward, I'll get them out to you as quickly as possible. Talk again soon. Get NBY on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) Fierce | 4834 NW 2nd Ave, Unit #388, Boca Raton, FL 33431 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net